Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$2.08 USD
-0.22 (-9.57%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $2.10 +0.02 (0.96%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Verrica Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 9 | 12 | 0 | 0 |
Cost Of Goods | 1 | 1 | 0 | 0 | 0 |
Gross Profit | 4 | 8 | 12 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 70 | 30 | 43 | 40 | 30 |
Income After Depreciation & Amortization | -66 | -21 | -31 | -40 | -30 |
Non-Operating Income | 3 | -1 | 0 | 1 | 2 |
Interest Expense | 4 | 2 | 4 | 3 | 0 |
Pretax Income | -67 | -24 | -35 | -43 | -28 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -67 | -24 | -35 | -43 | -28 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -67 | -24 | -35 | -43 | -28 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -65 | -20 | -30 | -40 | -30 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -66 | -21 | -31 | -40 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.34 | 34.16 | 27.05 | 25.00 | 24.90 |
Diluted EPS Before Non-Recurring Items | -1.14 | -0.66 | -1.25 | -1.71 | -1.13 |
Diluted Net EPS (GAAP) | -1.48 | -0.72 | -1.30 | -1.71 | -1.13 |
Fiscal Year end for Verrica Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 5.18 | 3.83 | 1.99 | 2.92 | 0.18 |
Cost Of Goods | 0.54 | 1.14 | 0.27 | 0.27 | 0.14 |
Gross Profit | 4.64 | 2.69 | 1.72 | 2.65 | 0.05 |
SG&A, R&D, and Dept/Amort Expenses | 19.84 | 21.29 | 22.32 | 26.56 | 11.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.20 | -18.60 | -20.60 | -23.91 | -11.62 |
Non-Operating Income | 0.39 | 0.59 | 0.83 | 0.77 | 0.63 |
Interest Expense | 2.37 | 2.32 | 2.31 | 1.66 | 0.00 |
Pretax Income | -17.19 | -20.33 | -24.61 | -24.80 | -10.99 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.19 | -20.33 | -24.61 | -24.80 | -10.99 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.19 | -20.33 | -24.61 | -24.80 | -10.99 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 46.50 | 46.48 | 46.31 | 46.07 | 45.92 |
Diluted EPS Before Non-Recurring Items | -0.37 | -0.44 | -0.48 | -0.32 | -0.24 |
Diluted Net EPS (GAAP) | -0.37 | -0.44 | -0.55 | -0.54 | -0.24 |